1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Autobahn Labs Partners with Astellas Pharma to Accelerate Academic Drug Discovery

13 Dec 2025
Admin
News Article

Autobahn Labs Partners with Astellas Pharma to Accelerate Academic Drug Discovery

Autobahn Labs has entered a strategic partnership with Astellas Pharma to help turn early academic research into real drug development programs.

The collaboration brings together Autobahn’s academic translation engine and Astellas’ global drug development expertise, with a shared goal: move promising science out of the lab and toward patients faster.

What the Partnership Covers?

Under the agreement, Astellas will gain early visibility into high-potential drug discovery programs emerging from Autobahn’s academic network.

Key elements of the collaboration include:

Exclusive investment opportunities for Astellas in selected programs created by Autobahn Labs
Co-investment and annual access fees paid to Autobahn Labs
Jointly formed Programme Companies to advance early-stage discoveries
Shared equity among Autobahn Labs, Astellas, academic institutions, and founding researchers
Right of first negotiation for Astellas to license resulting intellectual property

This structure allows academic discoveries to be developed in a focused, capital-efficient way, while preserving long-term commercial potential.

Bridging Academia and Industry

Autobahn Labs specializes in identifying strong academic science and building de-risked drug discovery programs around it.

By partnering with Astellas, these programs gain:

Early validation from a global pharma player
Access to real-world drug development expertise
A clearer path from discovery to clinical development

For Astellas, the partnership creates a steady pipeline of early, science-driven opportunities aligned with its innovation and oncology research priorities.

What Leaders Are Saying?

Dushyant Pathak, CEO of Autobahn Labs, said the collaboration combines academic innovation with world-class development capabilities.

Morten Søgaard, Head of Astellas Innovation Lab, highlighted the value of early access to high-quality academic research with strong translational potential.

Together, both companies aim to shorten the distance between breakthrough science and meaningful therapies.

Autobahn’s Growing Academic Engine

Autobahn Labs works with top academic institutions, including:

UCLA, UCSF, UC San Diego, and USC
University of Pennsylvania
Boston Children’s Hospital
Cold Spring Harbor Laboratory
Salk Institute and University of Michigan

The company is backed by Samsara BioCapital and Charles River Laboratories and operates as a venture studio focused on building investable biotech programs from academic research

Why This Matters?

Academic research produces some of the most innovative ideas in drug discovery.
But many never make it past the lab.

Partnerships like this solve that gap by:

Providing funding and structure early
Aligning science with real development pathways
Giving pharma companies earlier, smarter access to innovation

For patients, it means promising science has a better chance of becoming real medicine.